Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy (clinicaltrials.gov) - Oct 24, 2026 - P2 | N=26 | Recruiting | Sponsor: University of Michigan Rogel Cancer Center
New P2 trial • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|